IMUNON’s Phase 1/2 Trial Results On Intraperitoneal IMNN-001 + Neoadjuvant Chemo For Advanced Ovarian Cancer To Appear In Gynecologic Oncology

IMUNON, Inc., a clinical-stage biotechnology company focused on developing innovative DNA-mediated immunotherapies, has announced that comprehensive results from its Phase 1/2 OVATION 2 clinical trial will be published in the peer-reviewed journal “Gynecologic Oncology”. The publication is scheduled for June 3, 2025. The OVATION 2 trial is a randomized Phase 1/2 study evaluating the safety and efficacy of IMNN-001, an interleukin-12 (IL-12) gene therapy, administered intraperitoneally in combination with both neoadjuvant and adjuvant chemotherapy. 

The trial enrolled patients who were newly diagnosed with advanced epithelial ovarian cancer, aiming to assess whether the combination therapy could improve outcomes in this high-risk population. The full title of the publication is: “OVATION-2: A Randomized Phase I/II study Evaluating the Safety and Efficacy of IMNN-001 (IL-12 gene therapy) with Neo/Adjuvant Chemotherapy in Patients Newly-Diagnosed with Advanced Epithelial Ovarian Cancer”.

Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON, said in a statement, “We are very pleased that the data from our OVATION 2 study will be presented in the highly esteemed peer-reviewed journal Gynecologic Oncology and in an oral presentation at the ASCO meeting. Having our data presented in two of the premier global platforms in gynecologic oncology underscores both the critical need to develop new therapies to treat ovarian cancer and the strength and potential of IMUNON’s TheraPlas® platform technology.”

In addition to the upcoming journal publication, the OVATION 2 trial data will also be featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 3, 2025, in Chicago, Illinois. The presentation will be delivered by Dr. Premal H. Thaker, M.D., who serves as the Interim Chief of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, and Director of Gynecologic Oncology Clinical Research at Washington University School of Medicine. 

Dr. Thaker is the lead author of the publication and will lead the discussion during the ASCO presentation. This dual recognition—both through peer-reviewed publication and a high-profile scientific conference presentation—highlights the significance of the OVATION 2 study findings and IMUNON’s continued progress in advancing novel immunotherapy options for ovarian cancer patients.